QLS31905

QLS31905 is an investigational agent whose form is not stated in the registry developed by Qilu Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: QLS31905 will be administered as an IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07079228 (A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer), in pancreatic ductal adenocarcinoma. The largest, NCT07079228, plans to enrol 602 participants with primary completion expected 2028-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.